Immunogistochemical Characteristics of Breast Fibroadenoma Disease in Women Living in Aral Sea Region
Keywords:
breast cancer, dyshormonal diseases, immunohistochemical, mastopathy, dyshormonal hyperplasia, fibroadenoma, precancerous diseasesAbstract
Breast cancer (BC),- the most common cancer in women is considered. 1.5 million new cases are detected every year and this is 25% of all malignant tumors. The incidence is growing rapidly in European countries. Especially often this process develops against the background of dyshormonal processes, based on this, a retrospective analysis was carried out in order to identify the role of dyshormonal pathology in the development of precancerous diseases.
References
Atakhanova N.E., Almuradova D.M. Molecular-biological characteristics of trijdy negativnogo rak molochnoy zhelevy // Rossiyskiy bioterapevticheskii zurnal. - Moscow, 2018. - T. 17, No. 1. - S. 23-27
Imyanitov E.N. The role of molecular genetic diagnostics and practical oncology / E.N. Imyanitov // Practical oncology. – 2019. – T.4. - S. 261-273.
Semiglazov V.F., Semiglazov V.V., Kletsel A.E. Non-invasive and invasive swelling mammary glands. SPb., 2006. C. 6–60.
Smetnik V.P. Pollovye hormony i molochnaya zheleza / V.P. Smetnik // Gynecology. - 2000. - No. 2. - S.133-135.
Sabirov A.H., Kormina O.S., Alexin I.E., Khasanova G.R., Mustaev .3., Izgeim V.P., Nyamtsu AM, Baryshnikov A.Yu., Bychkov V.G. Correlation gkotorykh immunologicheskikh, immunofermentnykh i mokulyarno-:neticheskikh markerov v diagnostike opukholevogo rosta/Vserossiyskaya conference "Novye otechestvennye protivooopukholevye preparaty" 23-24 fev-1 2005g.- M„ 2005. -S. 37-41.
Kim A.Ya. Issledovanie NSABP B-04 25 years down the drain: a lesson for a modern oncologist / A.Ya. Kim, L.I. Markushin, S. A. Volchyonkov, V.K. Osetnik and dr. // Female reproductive system with swelling. – 2019. – T.2. - S. 52-56.
Miryusupova G.F. Clinical characteristics of HeR2-positive breast cancer / G.F. Miryusupova, G.A. Khakimov, N.R. Shayusupov // Voprosy oncology. – 2017. – T.4. - S. 587-592.
Ashbeck EL, Rosenberg RD, Stauber PM, Key CR Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16(3): 467–72.
Barrat J., de Lignieres B., Marpeau L. et al. Effet in vivo de l'administration locale de progesterone sur l'activité mitotique des galactophores humanas. J Gynecol Obstet Biol Reprod (Paris) 1990;19(3):269–74.
Colditz GA, Bohlke K., Berkey CS Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res Treat 2014;145(3):567–79.
Nassar A.,Visscher DW, Degnim AC et al. Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study. Breast Cancer Res Treat 2015;153(2):397–405.
Olivotto IA, Truong PT, Speers CH et al. Time to stop progesterone receptor testing in breast cancer management // Journal Clinical Oncology. - 2004. - Vol. 22. – No. 9. – P. 1769–1770.
Visscher DW, Nassar A., Degnim AC et al. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat 2014;144(1):205–12.
Obr AE, Edwards DP The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 2012;357(1):4–17.
Strange R. Apoptosis in mouse mammary gland development / R. Strange // Experientia. -1991. -№47.- P.105.
SJChoi, NEAtakhanova, NRShayusupov, DMIshakov, AJKahharov. Breast cancer recurrence clinical-pathological risk factors// World journal of pharmaceutical and medical research. -Delhi, 2019 №5 (4)-P. 19-22 (14.00.00; №9)
